Bristol Myers Squibb vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 10/13/26
Federal and state regulators asked a judge to hold “pharma bro” Martin Shkreli in contempt, alleging he traded drug stocks despite a lifetime ban from the pharmaceutical industryWSJ • 10/13/26
FTC says Martin Shkreli 'flagrantly and repeatedly' violated his lifetime pharma banBusiness Insider • 10/13/26
‘Pharma Bro' Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocksMarket Watch • 10/13/26
Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market TodayZacks Investment Research • 10/12/26
BMY Surges 35.7% in a Year: Should You Buy, Sell or Hold the Stock?Zacks Investment Research • 10/12/26
Bristol Myers Scores Two Phase 3 Wins, But A Key Rival Plummets On OneInvestors Business Daily • 10/12/26
Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio's Radiopharmaceutical Therapy, in Patients with GEP-NETsBusiness Wire • 10/12/26
Bristol Myers Squibb Announces Phase 3 ALOFT-IPF Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary EndpointBusiness Wire • 10/12/26
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 10/10/26
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 10/09/26
Will Bristol Myers (BMY) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 10/08/26
Bristol Myers Squibb's Zenbexus Delivers Major Blood Cancer Win, Cuts Progression Risk 51%Benzinga • 10/08/26
Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs.Business Wire • 10/08/26
Bristol-Myers Squibb: Balanced Segment Growth, The Pullback Is An OpportunitySeeking Alpha • 10/07/26
5 Dividend Stocks With Fortress-Like Coverage and Room for Things to Go Wrong24/7 Wall Street • 10/07/26
3 Stocks With Broker Rating Upgrades Amid Resilient Equity MarketsZacks Investment Research • 10/05/26